Rigel Pharmaceuticals RIGL Accrued Rebates, Returns, and Promotions
Accrued Rebates, Returns, and Promotions at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerRefundLiabilityCurrent.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's accrued rebates, returns, and promotions.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's accrued rebates, returns, and promotions?
- Rigel Pharmaceuticals (RIGL) reported accrued rebates, returns, and promotions of $28.08M in Q1 2026.
- How has Rigel Pharmaceuticals's accrued rebates, returns, and promotions changed year-over-year?
- Rigel Pharmaceuticals's accrued rebates, returns, and promotions increased by 0.5% year-over-year, from $27.94M to $28.08M.
- What is the long-term trend for Rigel Pharmaceuticals's accrued rebates, returns, and promotions?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's accrued rebates, returns, and promotions has grown at a 36.8% compound annual growth rate (CAGR), from $7.92M to $27.72M.
- What does accrued rebates, returns, and promotions mean?
- This liability account captures estimated future outflows related to customer rebates, product returns, and promotional incentives offered to distributors or healthcare providers. It is a critical contra-revenue adjustment that reflects the net realizable value of product sales. High levels may indicate aggressive sales practices or potential issues with product demand and market acceptance.